Peak Frameworks

SEPTEMBER 19, 2023

For example, in the 2012 Facebook IPO, common shareholders gained exposure to the tech giant's fortunes, while also securing a say in corporate matters. By virtue of their ownership, they possess a direct financial interest in the company's success.

Corporation 52

Corporation Private Equity Mergers and Acquisitions Corporate Finance 52

Cooley M&A

JANUARY 25, 2023

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 20, 2022

In November, Johnson & Johnson announced that it will split itself into two publicly traded companies , separating its pharmaceutical and medical devices businesses from its consumer products business. billion strategic combination of One Medical and Iora Health – used all stock. [9] time highs in 2021.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40

Cooley M&A

JANUARY 25, 2023

The rules are expected to increase the frequency of proxy contests (particularly by less-established activists), afford dissidents increased leverage in settlement negotiations, and increase focus on the strength and qualifications of individual directors.

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52

Cooley M&A

JANUARY 22, 2025

This approach, combining M&A and initial public offering (IPO) preparations on parallel tracks, allows companies to maximize optionality in an uncertain market. Of course, the targets leverage in the M&A track of a dual-track process inherently increases when the IPO track is a viable strategy.

M&A 64

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 64